RIPK1 inhibitor for enhancing hair growth and treating alopecia
A novel RIPK1 inhibitor, Necrostatin-1, promotes hair growth by inhibiting necroptosis, potentially treating androgenetic alopecia and alopecia areata. Seeking partners for clinical trials.
Overview
Necrostatin-1 (Nec-1) is a revolutionary RIPK1 inhibitor developed to enhance hair growth by inhibiting necroptosis, a process involved in regulating the hair cycle. This innovative approach targets androgenetic alopecia and may also be effective for alopecia areata, offering a promising new treatment avenue for individuals suffering from hair loss.
Technical specifications
Key features:
- RIPK1 Inhibition: Nec-1 effectively inhibits necroptosis, which is crucial in the regulation of the hair cycle, thereby promoting hair growth.
- Targeted Treatment: Designed specifically for androgenetic alopecia, with potential applications in treating alopecia areata.
- Mechanism of Action: By targeting and inhibiting necroptosis, Nec-1 supports the natural hair cycle and stimulates growth.
Technology readiness level
This technology is currently at TRL 4, having been validated in a lab environment. The next stage involves seeking partnerships or licensing opportunities for the development of clinical trial samples to further validate efficacy and safety in a clinical setting.
About Epibiotech
Epibiotech is a South Korean biopharmaceutical company specializing in the development of innovative treatments for alopecia. The company leverages a proprietary AI-driven drug discovery platform, Hair.I., which integrates a large genomic database, single-cell analysis, and AI screening to identify novel hair loss targets. Their research focuses on advanced modalities, including autologous and allogeneic dermal papilla cell therapies and neutralizing antibody treatments, designed to stimulate hair follicle regeneration and address the underlying causes of hair loss such as androgenetic factors.
These therapeutics provide targeted solutions for patients suffering from hair loss, aiming to offer more effective, science-based restoration compared to conventional treatments. By combining its drug development pipeline with non-clinical CRO expertise for efficacy evaluation, Epibiotech supports the advancement of hair science from discovery to clinical trials. The company has reached significant milestones, including initiating clinical trials for its lead cell therapy candidate, EPI-001, and securing recognition through international biotech innovator awards.
delivered to your inbox.